Non-compliance, requests for generics on the rise, says survey

Share this article:
Physicians say patient compliance is getting worse, and they're hearing more requests for generic or OTC alternatives to prescribed medications as the economic malaise takes its toll, according to a Pri-Med survey.

Of the 473 respondents, 70% said they are hearing patients increasingly request generic or OTC alternatives, and 68% said they've noticed an increase in non-compliant behaviors with regards to medication usage among patients. More than half said they're seeing changes in patient payment, such as increased delinquencies or requests for payment plans, and 88% are seeing changes to patients' appointment behaviors, including increased cancellations and refusals of tests or screening procedures.

As a result, clinicians reported spending more time with patients at the point of care discussing prescription alternatives or the importance of compliance and prevention. They're also devoting more time to investigating lower-cost treatment options and formulary specifics to help out their patients, and more than three-quarters said they're making changes to their practice such as taking steps to minimize cancellations, expanding payment options and offering online or phone-based consultations.

The web-based poll, conducted from May 14 to May 21, was emailed to more than 16,000 Pri-Med alumni clinicians and garnered a response rate of 3%, the company said.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.